Press Releases

 
Press Releases
  Date Title View
Jun 10, 2016
-  Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471  - -  Results support initiation of phase 1 multiple-ascending trial during the second quarter and phase 2 studies for paroxysmal ...
PDF
Jun 1, 2016
NEW HAVEN, Conn., June 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences: Jefferies 2016 Healthcare...
PDF
May 19, 2016
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers - NEW HAVEN, Conn., May 19, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACH...
PDF
May 3, 2016
-  Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 — -  Strong balance sheet to support planned 2016 clinical expansion of ACH-4471, Achil...
PDF
Apr 28, 2016
NEW HAVEN, Conn., April 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016 at ...
PDF
Mar 3, 2016
NEW HAVEN, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Cowen and Company 36t...
PDF
Feb 25, 2016
NEW HAVEN, Conn., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve month periods ending December 31, 2015. For the three months ended December 31, 2015, the Company reported net income of $17.0 million, comp...
PDF
Feb 11, 2016
NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company's first orally-administered, highly potent and specific small molecule that has been shown to inhibit complement factor D. The phase 1 study...
PDF
Feb 8, 2016
NEW HAVEN, Conn., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February...
PDF
Feb 3, 2016
NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, P...
PDF
1
...
NextLast
Achillion Pharmaceuticals